Surgery Partners Reports Reduced Net Loss, Revenue Growth, and Authorizes $200M Share Buyback Amidst Regulatory Headwinds

summarizeSummary

Surgery Partners reported a reduced net loss, increased revenue and Adjusted EBITDA for 2025, and authorized a new $200 million share repurchase program, signaling management confidence despite ongoing regulatory challenges.

check_boxKey Events

• Reduced Net Loss and Revenue Growth

  The company reported a net loss of $77.9 million for 2025, a significant improvement from $168.1 million in 2024. Total revenues increased by 6.2% to $3.3 billion, and Adjusted EBITDA grew by 3.5% to $526.2 million.

• New $200 Million Share Repurchase Program

  The Board of Directors authorized a new share repurchase program of up to $200.0 million on February 26, 2026, replacing a previous $50.0 million authorization. This represents a substantial increase in potential capital return to shareholders.

• Debt Refinancing and Note Issuance

  In August 2025, Surgery Partners refinanced $1.383 billion in term loans at a lower interest rate (Term SOFR + 2.50%). In December 2025, the company issued $425.0 million in senior unsecured notes due 2032 at 101.00% of principal, using proceeds to repay revolver borrowings and for general corporate purposes.

• Active Portfolio Management

  During 2025, the company acquired controlling interests in 12 surgical facilities and other businesses for $162.1 million, and disposed of interests in several facilities for $46.5 million, realizing net gains.

auto_awesomeAnalysis

Surgery Partners' annual report for 2025 reveals a significant reduction in net loss, alongside solid revenue and Adjusted EBITDA growth. The company reported a net loss of $77.9 million, a substantial improvement from $168.1 million in 2024, indicating progress towards profitability. Revenue increased by 6.2% to $3.3 billion, and Adjusted EBITDA grew by 3.5% to $526.2 million. A key development is the Board's authorization of a new $200.0 million share repurchase program, replacing a smaller $50.0 million program. This substantial increase in buyback capacity, especially with the stock trading near its 52-week lows, signals strong management confidence in the company's valuation and future prospects. The company also actively managed its debt, refinancing $1.383 billion in term loans at a lower interest rate (Term SOFR + 2.50%) and issuing $425.0 million in senior unsecured notes at a premium (101.00%), demonstrating favorable access to capital despite a high overall debt load of $3.7 billion. However, the report highlights significant regulatory risks, including the expiration of Affordable Care Act subsidies and the 'One Big Beautiful Bill Act' (OBBBA), which are expected to increase premiums, reduce enrollment, or shift patients to government programs, potentially impacting future financial performance. While the company states OBBBA is not expected to materially impact financial statements, these are notable long-term risks to monitor.